The pharmaceutical giant, Cipla Ltd has recently bought four women-centric nutraceutical brands from the drug-making company, Wanbury Ltd.
The four brands -- CPink, CDense, Productiv, and Folinine -- have a market size of INR 3,100 crore in India with a sales value of INR 59.6 crore, VC Circle reported citing Ciplas officing statement in a stock market disclosure.
The acquisition will help the company cater to a wide range of patient needs including nutritional deficiencies and bone and sexual health, Nikhil Chopra, Head of India business at Cipla, said in the companys official statement.
These brands primarily comprise supplements like multi-minerals, multivitamins, and women going through menopause, antioxidants for adolescent females, pregnant and lactating mothers, and for male as well as female reproductive health.
Wanbury, which is established in 1990, operates in the marketing, as well as sales, of active pharmaceutical ingredients (APIs) in more than 50 nations, as per its website. It has extended its roots in the formulation business as well.
In recent times, the women-centric pharmaceutical niche viewed a major transaction when a private equity company, Ascent Capital infused money in Naari Pharma.
Cipla, which was founded in 1935, procured various companies in the previous year. In December 2019, the pharmaceutical company bought brand as well as trademark rights for Vysov and Vysov M of the anti-diabetic drug Vildagliptin for the local market from Novartis AG, reported VC Circle.